Nathan Weinstein
Stock Analyst at Aegis Capital
(0.26)
# 4,340
Out of 5,050 analysts
61
Total ratings
13.33%
Success rate
-26.26%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.16 | +6,796.55% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $400 → $300 | $12.50 | +2,300.00% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.39 | +1,434.53% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.72 | +4,770.58% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.72 | +120.59% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.19 | +1,269.86% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $11.01 | -9.17% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $17.56 | +179.04% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $63,000 → $1,800 | $6.11 | +29,359.90% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $3.73 | +57,808.85% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $2.64 | +4,445.45% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.96 | +936.48% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $104.39 | +53.27% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $33.19 | +68.73% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $4.36 | +519.27% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.60 | +5,782.35% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.14 | +282.17% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $8.66 | +766.05% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $2.46 | +3,477.24% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $3.99 | +4,411.28% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.67 | +2,790.79% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.10 | +129.51% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $15.71 | +1,300.38% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $4.19 | +102.86% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.16
Upside: +6,796.55%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400 → $300
Current: $12.50
Upside: +2,300.00%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.39
Upside: +1,434.53%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.72
Upside: +4,770.58%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.72
Upside: +120.59%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.19
Upside: +1,269.86%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $11.01
Upside: -9.17%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $17.56
Upside: +179.04%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000 → $1,800
Current: $6.11
Upside: +29,359.90%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.73
Upside: +57,808.85%
Dec 7, 2021
Initiates: Buy
Price Target: $120
Current: $2.64
Upside: +4,445.45%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.96
Upside: +936.48%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $104.39
Upside: +53.27%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $33.19
Upside: +68.73%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $4.36
Upside: +519.27%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.60
Upside: +5,782.35%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $3.14
Upside: +282.17%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $8.66
Upside: +766.05%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $2.46
Upside: +3,477.24%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $3.99
Upside: +4,411.28%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.67
Upside: +2,790.79%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $6.10
Upside: +129.51%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $15.71
Upside: +1,300.38%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $4.19
Upside: +102.86%